Exendins and exendin agonists modified with albumin
US7608692B2 · kind B2 · utility
41Cited by
31References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 11, 2008 |
| Grant date | Oct 27, 2009 |
| Priority date | — |
| Expiry date | Apr 11, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.